This case report describes the case of a 55-year-old woman with end-stage renal disease (ESRD) due to IgA nephropathy who had received two renal transplantations, in 1988 and 1999. In the following 10 years, her renal function gradually deteriorated owing to chronic rejection, and uraemic signs such as anasarca and oliguria inevitably developed. Stepwise initiation of peritoneal dialysis using peritoneal dialysis catheter implantation by the Moncrief and Popovich technique was conducted in August 2009, and the immunosuppressant was then switched to sirolimus (Rapamune 1 mg/day) for better rejection control. During the procedure, the flushed peritoneal drain from the implanted Tenckhoff catheter was clear. However, on extraction of the buried catheter in November for intolerable uremia, milky-like ascites was noted ([Figure 1](#SFT153F1){ref-type="fig"}). Biochemical study of the turbid peritoneal dialysate showed an elevated white cell counts (WBC 200/mm^3^) with 100% lymphocytes, and dialysate cultures did not yield any pathogens. The triglyceride level in the dialysate was 15.98 mmol/L, and the serum triglyceride level was 11.99 mmol/L. Chylous ascites was diagnosed. Subsequent studies including malignancy work-ups and anatomic obstructive causes of lymph vessels were all negative. On reviewing the patient\'s medications, no calcium-channel blocker was prescribed. Fig. 1.The right side shows chylous peritoneal dialysate; the left side is normal dianeal.

After excluding the main causes of chylous ascites, sirolimus (1 mg/day) was considered to be the major offending agent. After tapering of the sirolimus, the peritoneal dialysate became clear and the dialysate triglyceride level declined to 5.16 mmol/L.

Chylous ascites are uncommon, and the milky appearance is due to a high triglyceride content, \>11.1 mmol/L. In general, the main causes of chylous ascites involve disruption of the lymphatic system from trauma, obstruction due to abdominal malignancy or cirrhosis, infection such as tuberculosis, and medication, for example a calcium-channel blocker (Table [1](#SFT153TB1){ref-type="table"}) \[[@SFT153C1], [@SFT153C2]\]. However, additional differential diagnoses of chylous ascites in renal transplantation patients include surgical lymph vessel injury and the immunosuppressant agent sirolimus \[[@SFT153C3]\]. Regarding surgical related lymph vessel injury, lymphoceles usually occurs in the first 6-months post-transplantation. Table 1.Differential diagnosis of chylous ascites in post-transplant adult peritoneal dialysis patient1. Anatomical structure deficitA. CongenitalB. acquired, e.g. trauma2. Postoperative complicationA. Surgery-related damage to chyle-containing lymphatic channels, e.g. Tenckhoff catheter insertingB. Lymphocele formation: usually within first 6-months post-transplantation3. Malignancy-relatedA. Abdominal malignancy resulting lymph obstruction, e.g. lymphoma, other malignancies4. Severe inflammationA. Post-radiotherapy of retropheritoneumB. Retroperitoneal fibrosisC. Nephrotic syndromeD. Liver cirrhosisE. Pancreatitis5. Infection: Tuberculosis (most commonly), disseminated mycobacterium avium complex (MAC) infection, and filariasis6. Drugs: felodipine, sirolimus

Sirolimus has been increasingly used in transplantation medicine \[[@SFT153C4]\]. The side effects of sirolimus treatment are dose dependent, and include hyperlipidemia, anemia, thrombocytopenia, hepatotoxicity, delayed wound healing and a high rate of lymphoceles, lymph edema and pulmonary alveolar proteinosis \[[@SFT153C5]\]. The risk of sirolimus-related lymphoceles is 12--15% \[[@SFT153C3]\]. The mechanism of sirolimus-induced lymphoceles is unclear, but may be related to disruption of proliferative signals necessary to seal perivascular lymphatics and to promote wound healing \[[@SFT153C4]\]. After the main causes of chylous ascites are excluded, sirolimus toxicity should be considered. Switching sirolimus to other immunosuppressive agents led to complete resolution.
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